Xenikos B.V. is located in Nijmegen, Netherlands on Wilhelminasingel 14. Xenikos B.V. is rated 3 out of 5 in the category pharmaceutical company in Netherlands. Xenikos, a private, clinical-stage biopharmaceutical company, is focused on developing innovative immunotherapies, based on conjugated antibodies, designed to quickly and safely reset the immune system in patients with a severe immune disease or post-transplantation rejection. Xenikos’ flagship product, T-Guard®, is being prepared to enter Phase 3 testing for the treatment of acute graft-versus-host-disease.
Address
Wilhelminasingel 14
Company size
1-10 employees
Headquarters
Nijmegen, Gelderland
Accessibility
Wheelchair-accessible entrance